Mesoblast (NASDAQ:MESO) Stock Breaks Above 200 Day Moving Average – Here’s Why

Shares of Mesoblast Limited (NASDAQ:MESO) crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $15.45 and traded as high as $15.82. Mesoblast shares last traded at $15.67, with a volume of 696,476 shares trading hands.

Key Headlines Impacting Mesoblast

Here are the key news stories impacting Mesoblast this week:

• Positive Sentiment: Ryoncil revenue increased 44%. Mesoblast reported a 44% year-over-year increase in net revenue for the first quarter of fiscal 2027, led by stronger Ryoncil sales. Continued uptake could support a more favorable valuation for the company’s commercial-stage business. Mesoblast Stock Jumps on Ryoncil Sales and Lower Cash Burn
• Positive Sentiment: Cash burn fell sharply. The quarterly update showed materially lower cash spending, improving Mesoblast’s financial outlook and potentially extending its cash runway. This was a major reason investors responded favorably to the report. Mesoblast Quarterly Activity Report
• Positive Sentiment: Investors are reassessing Ryoncil’s commercial potential. Coverage highlighted the possibility that sustained prescription growth and revenue expansion could change the investment case for Mesoblast, helping drive heavy trading volume and a broad rally in the stock. Ryoncil Growth Could Change the Case for Mesoblast Stock
• Neutral Sentiment: Mesoblast’s move also occurred within a wider advance in healthcare and biotechnology shares, so sector-wide risk appetite may have amplified the company-specific reaction. Healthcare Stocks Rise
• Negative Sentiment: Mesoblast remains an early commercial-stage biotechnology company with continuing execution, profitability and regulatory risks. The rally could remain volatile if Ryoncil growth slows or quarterly cash use increases again.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on MESO shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a report on Thursday, September 24th. Weiss Ratings raised shares of Mesoblast from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Finally, Piper Sandler restated an “overweight” rating and set a $39.00 target price (up from $35.00) on shares of Mesoblast in a research report on Thursday, August 27th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Mesoblast presently has a consensus rating of “Hold” and a consensus price target of $39.00.

Mesoblast Trading Up 17.0%

The company has a current ratio of 2.43, a quick ratio of 2.09 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average price of $14.98 and a two-hundred day moving average price of $15.45.

Mesoblast (NASDAQ:MESO) last released its quarterly earnings data on Friday, July 31st. The company reported ($0.07) EPS for the quarter. The firm had revenue of $34.45 million for the quarter. As a group, sell-side analysts predict that Mesoblast Limited will post -0.05 earnings per share for the current fiscal year.

Institutional Trading of Mesoblast

Several institutional investors and hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Mesoblast in the third quarter worth $39,000. GAMMA Investing LLC increased its holdings in shares of Mesoblast by 14.1% in the 2nd quarter. GAMMA Investing LLC now owns 7,413 shares of the company’s stock worth $100,000 after buying an additional 916 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Mesoblast by 15.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,566 shares of the company’s stock valued at $142,000 after buying an additional 1,247 shares in the last quarter. Royal Bank of Canada raised its position in shares of Mesoblast by 22.5% during the 1st quarter. Royal Bank of Canada now owns 26,266 shares of the company’s stock valued at $404,000 after buying an additional 4,827 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Mesoblast by 608.4% during the 1st quarter. Bank of America Corp DE now owns 100,004 shares of the company’s stock worth $1,538,000 after acquiring an additional 85,888 shares during the last quarter. 1.43% of the stock is currently owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited is an Australia-based biotechnology company focused on developing and commercializing regenerative medicines made from specialized allogeneic mesenchymal lineage cells. The company’s platform is designed to produce “off-the-shelf” cellular therapies intended to address inflammation, tissue damage and impaired healing without requiring cells to be collected from each individual patient.

Mesoblast’s lead product, remestemcel-L, is marketed in the United States as RYONCIL.